0.46  0.14 (43.71%)		05-15 15:28
Open: 0.47 High: 0.52 Volume: 750		Pre. Close: 0.3201 Low: 0.33 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.6	1-year :	0.7
Resists	First :	0.51	Second :	0.6
Pivot price	0.32
Supports	First :	0.39	Second :	0.31
MAs	MA(5) :	0.35	MA(20) :	0.33
	MA(100) :	0.32	MA(250) :	1.23
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	28.4	D(3) :	19.8
RSI	RSI(14): 66.8
52-week	High :	8.27	Low :	0.23

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ XAGE ] has closed Bollinger Bands are 6.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.52 - 0.52	0.52 - 0.52
Low:	0.33 - 0.33	0.33 - 0.33
Close:	0.46 - 0.46	0.46 - 0.46

Longevity Health Holdings Inc focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Fri, 15 May 2026
Longevity Health (XAGE) registers 44,382 shares; cash $313K, going‑concern flagged - Stock Titan

Wed, 08 Apr 2026
Ajjarapu-led investor takes 27.9% of Longevity Health (XAGE) and CEO role - Stock Titan

Tue, 17 Mar 2026
New Longevity Health chief takes equity stake to lead acquisition push - Stock Titan

Tue, 17 Mar 2026
Longevity Health Holdings Appoints Ram Ajjarapu as Chairman & CEO, Closes Strategic Investment to Accelerate Acquisition Growth - Minichart

Tue, 17 Mar 2026
Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth - Yahoo Finance

Tue, 15 Jul 2025
Why did XAGE Stock Surge in Today’s Premarket Trading? - Tokenist

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	2 (M)
Held by Insiders	1.67e+006 (%)
Held by Institutions	36 (%)
Shares Short	25 (K)
Shares Short P.Month	0 (K)

EPS	-6.68e+006
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-483.2 %
Return on Assets (ttm)	-220 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	2 %
Gross Profit (p.s.)	2164.28
Sales Per Share	6.82143e+006
EBITDA (p.s.)	5.14286e+006
Qtrly Earnings Growth	-4.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-0.06

Dividend	0
Forward Dividend	8830
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.